Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. - Lo SH; Gorni K; Sutherland CS; Martí Y; Lloyd A; Paracha N (PharmacoEconomics, 2022)